IPO Watch: Novacea In-licenses Cancer Drugs

May 5, 2006 -- Novacea is on the schedule to make its IPO during the week of May 8, a date that was slipped from the week before. Novacea focuses on in-licensing cancer drugs, with three compounds in clinical trials. We look at its drugs and its finances, as the IPO market for biotechs stays very active...

Back to news